Prima BioMed (NASDAQ:IMMP) Stock Crosses Below 50-Day Moving Average – Should You Sell?

Prima BioMed Ltd (NASDAQ:IMMP)’s stock price crossed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $0.42 and traded as low as $0.3815. Prima BioMed shares last traded at $0.3889, with a volume of 310,698 shares trading hands.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Prima BioMed in a report on Friday, July 10th. Maxim Group upgraded Prima BioMed from a “hold” rating to a “buy” rating in a report on Wednesday, June 17th. Finally, Wall Street Zen raised Prima BioMed to a “hold” rating in a research report on Saturday, April 18th. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Prima BioMed currently has a consensus rating of “Hold” and a consensus price target of $5.50.

Prima BioMed Stock Down 2.6%

The firm’s 50 day moving average price is $0.42 and its 200-day moving average price is $1.28.

Institutional Trading of Prima BioMed

An institutional investor recently raised its stake in Prima BioMed stock. Jane Street Group LLC grew its holdings in Prima BioMed Ltd (NASDAQ:IMMP) by 14.7% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 51,574 shares of the biotechnology company’s stock after purchasing an additional 6,617 shares during the period. Jane Street Group LLC’s holdings in Prima BioMed were worth $91,000 as of its most recent SEC filing. Institutional investors own 2.32% of the company’s stock.

Prima BioMed Company Profile

Prima BioMed, trading as IMMP on NASDAQ, is a clinical-stage biotechnology company specializing in the development of immunotherapy products for cancer treatment. The company’s core technology platform centers on targeting the lymphocyte activation gene-3 (LAG-3), a checkpoint receptor that modulates T-cell activity. Prima BioMed’s lead candidate, eftilagimod alpha (IMP321), is a soluble LAG-3 protein designed to enhance antigen-presenting cell function and stimulate a tumor-specific immune response.